Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 8/20 | 0.44 |
| ▸ | CTSK | P43235 | 7/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639344 | 0.88 | CTSS (0.46) | BCL2PTPN1CTSSCTSKITGB3 | |
| SCHEMBL21639347 | 0.88 | CTSS (0.46) | BCL2PTPN1CTSSCTSKITGB3 | |
| SCHEMBL15583670 | 0.85 | SCN9A (0.48) | SCN9AEGLN2BCL2PTPN1CTSS | |
| SCHEMBL6762817 | 0.84 | SCN9A (0.47) | SCN9AEGLN2BCL2PTPN1CTSS | |
| SCHEMBL3779708 | 0.82 | SCN9A (0.51) | SCN9AEGLN2BCL2PTPN1CTSS | |
| SCHEMBL3774503 | 0.80 | SCN9A (0.41) | SCN9AEGLN2GPR34 | |
| SCHEMBL31757466 | 0.78 | CTSS (0.42) | BCL2CTSSCTSKCTSBCTSL | |
| SCHEMBL29500880 | 0.77 | PPARG (0.47) | SCN9ABCL2PTPN1CTSSCTSK | |
| SCHEMBL3774707 | 0.77 | ACE (0.47) | SCN9ABCL2PTPN1CTSSCTSK | |
| SCHEMBL27873039 | 0.77 | ACE (0.47) | SCN9ABCL2PTPN1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | SCN9A 1463/4885EGLN2 4293/4885BCL2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.